Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. Academic Article uri icon



  • The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P< .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log(10) copies/mL at day 14 and -1.91 versus -0.57 log(10) copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.

publication date

  • December 1, 2009



  • Acquired Immunodeficiency Syndrome
  • Anti-HIV Agents
  • CCR5 Receptor Antagonists
  • HIV-1
  • Piperazines
  • Pyrimidines


PubMed Central ID

  • PMC2783913

Scopus Document Identifier

  • 70350179577

Digital Object Identifier (DOI)

  • 10.1086/648090

PubMed ID

  • 19874179

Additional Document Info


  • 200


  • 11